June 6 (Reuters) - Otsuka's 4578.T drug for a type of kidney disease showed over 50% reduction in protein in patient's urine in a late-stage trial, the Japan-based company said on Friday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.